The challenge of cross-trial comparisons using limited data

The manuscript by Dr David Siegel and colleagues,[1][1] “Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies”, provides a comprehensive assessment of the available safety data associated with the new proteasome inhibitor